The inhibitory γ-aminobutyric acid (GABA) neurotransmitter system is associated with the regulation of normal cognitive functions and dysregulation has been reported in a number of neuropsychiatric disorders including anxiety disorders, schizophrenia and addictions. Investigating the role of GABA in both health and disease has been constrained by difficulties in measuring acute changes in synaptic GABA using neurochemical imaging. The aim of this study was to investigate whether acute increases in synaptic GABA are detectable in the living human brain using the inverse agonist GABA-benzodiazepine receptor (GABA-BZR) positron emission tomography (PET) tracer, [ 
disease has been constrained by difficulties in measuring acute changes in synaptic GABA using neurochemical imaging. The aim of this study was to investigate whether acute increases in synaptic GABA are detectable in the living human brain using the inverse agonist GABA-benzodiazepine receptor (GABA-BZR) positron emission tomography (PET) tracer, [ reduction in the nucleus accumbens. These reductions were greater than test-retest reliability, indicating that they are not the result of chance observations. Our results suggest that acute increases in endogenous synaptic GABA are detectable in the living human brain using [ Introduction Gamma-aminobutyric acid (GABA) is the most important and ubiquitous inhibitory neurotransmitter in the brain. The GABA system is associated with a number of important cognitive functions including memory (Michels et al., 2012) , attention (Smolnik et al., 1998) and associative learning (Makkar et al., 2010) . Dysregulation within the GABA system has been reported in many neuropsychiatric disorders, such as anxiety and panic disorders (Malizia et al., 1998) , epilepsy (Baulac et al., 2001; Loup et al., 2000) , schizophrenia (Ahn et al., 2011; Hoftman et al., 2013) , and addiction . The ability to image synaptic GABA levels in the living human brain is therefore critical for our understanding of the role of the GABA system in both health and disease.
Currently, human GABA in vivo neuroimaging research predominantly uses positron emission tomography (PET) to quantify GABA-benzodiazepine receptor (GABA-BZR) availability and magnetic resonance spectroscopy (MRS) to index overall GABA levels. However, GABA MRS has a number of limitations such as difficulties isolating GABA in the spectrum, the need to sample very large voxels, and difficulties in interpreting how much of the MRS signal originates from the neurotransmitter or synaptic pool compared with the larger metabolic pool. Thus, although MRS studies report differences in GABA levels in clinical populations, such as in unipolar depression (Sanacora et al., 1999) or after anticonvulsant treatment in epilepsy (Doelken et al., 2010) , it is impossible to say whether these differences are neurotransmitter or metabolic in origin. In addition, the sensitivity of GABA MRS to measure expected acute changes in synaptic GABA levels after a pharmacological Paul Stokes et al. 6 challenge is inconsistent (Henry et al., 2010; Kupers et al., 2009; Valentine et al., 2011) . In contrast, PET offers a unique opportunity to assess dynamic changes in synaptic GABA levels.
Two PET ligands, [ neurochemical imaging of the human GABA system and both bind to the benzodiazepine site on the GABA-A receptor. GABA-benzodiazepine receptors (GABA-BZR's) contain two subunits from one of six α subunits (α1-α6); GABA-BZR's containing α1-α3 subunits are located intra-synaptically and those containing α4-α6
are predominantly or exclusively located extra-synaptically (Brunig et al., 2002; Kasugai et al., 2010) . Measurement of synaptic GABA levels using PET is therefore theoretically dependent on the ability to isolate a specific synaptic α1-α3 signal.
[ 11 C]Flumazenil, the more commonly used radioligand, binds with similar affinity to α1-α3 and α5 subtypes and also with somewhat lower affinity to α4 and α6 subtypes (Hadingham et al., 1993) . It is not therefore currently possible to isolate a specific synaptic GABA-BZR PET signal using [ (Hadingham et al., 1993) . We have recently shown that a specific α1 subtype signal can be quantified in [ 11 C]Ro15-4513 PET studies, by partitioning fast and slow ligand kinetics using spectral analysis .
The pharmacological properties of Ro15-4513 also offer further advantages over flumazenil. Ro15-4513 is an inverse GABA-BZR agonist whereas flumazenil is generally considered to be an antagonist. The affinity of benzodiazepine full agonists or partial agonists, but not antagonists, at the GABA-BZR can alter as a result of Paul Stokes et al. 7 changes in synaptic GABA levels -the so called GABA shift (Braestrup et al., 1982; Tallman et al., 1978 (Onoe et al., 1996; Tyacke et al., 2009) . However, whilst flumazenil shows no GABA shift in vitro (Braestrup et al., 1982) , in some circumstances in vivo it appears to behave as a partial agonist (Higgitt et al., 1986; Miller et al., 1988) (Frankle et al., 2012; Frankle et al., 2009 ).
The aim of this present study was to determine whether a reduction in synaptic α1-subtype GABA-BZR affinity produced by increases in synaptic GABA levels could be detected in the living human brain. We used tiagabine, which increases synaptic GABA levels by selectively inhibiting the GABA transporter 1 (GAT1) in experimental animal studies (Fink-Jensen et al., 1992; Richards and Bowery, 1996; Sybirska et al., 1993) and in a human case report (During et al., 1992) . Tiagabine also produces physiological changes consistent with increased GABA concentrations in recent MEG studies (Muthukumaraswamy et al., 2013; Muthukumaraswamy et al., 2012) .
Our hypothesis was that tiagabine administration would increase synaptic GABA levels and hence reduce the affinity and binding of [ 
Material and methods

Participants
Twelve healthy male participants (mean age 50.1 years ± SD: 7.1; 6 non-cigarette smokers, 5 ex-cigarette smokers, 1 participant with unknown smoking status) completed the tiagabine challenge study, and four healthy male participants (mean age 41.5 years ±SD: 4.4; 3 non-smokers, 1 participant with unknown smoking status) completed the test-retest reliability study. Exclusion criteria for all participants included current or previous significant mental health disorders, alcohol or recreational drug dependency as defined by DSM-IV, serious physical illness, past neurological disorders, and previous use of psychotropic medications. Potential participants underwent urine drug screening to exclude recent recreational drug use prior to their enrolment in the study. For the tiagabine challenge study participants' baseline anxiety and depression symptoms were assessed using the Beck Depression Inventory (BDI) (Beck et al., 1961) and the Spielberger Trait Anxiety Inventory (STAI) (Spielberger et al., 1970) . Verbal and visuospatial memory was assessed using the logical memory subtest of the Wechsler Memory Scale (Wechsler, 1981) Twenty four dynamic frames (1x30, 4x15, 4x60, 2x150, 10x300, 3x600 s) of data were acquired in 3D mode over 90 min and produced images containing 63 contiguous slices. Arterial blood sampling was used to produce a metabolitecorrected plasma input function as described previously (Lingford-Hughes et al., 2002) .
MR Imaging
All participants underwent a structural T1 MRI scan for co-registration purposes. MRI scans were acquired using a 1.5T scanner for tiagabine challenge participants (1.5
Eclipse system, Marconi Medical Systems, Cleveland, OH, USA; TR=30 ms, TE=3ms, flip angle=30º, NSA=1, voxel dimensions 0.98x1.6x1.6mm All dynamic scans were corrected for head movement using frame by frame (FBF) realignment (Montgomery et al., 2006) . This procedure was applied to all frames to generate a FBF corrected dynamic image, which was then analysed using an automated region of interest (ROI) . Spectral analysis (Cunningham and Jones, 1993; Turkheimer et al., 1994 ) is a basis function technique, used to convolve the plasma input function with first order poly-exponentials, to fit regional TAC data, assuming system linearity and timeinvariance. The "spectrum" of dissociation rates, each represented by one or several closely related peaks, that effect the shape of the TAC can be divided into ranges that represent the different compartments of [ 
Statistical Analysis
Scan data and demographics were assessed using two-tailed t-tests. For the tiagabine challenge dataset, decreases in α1-specific V S values in a prori ROIs were assessed using a one-tailed paired t-test, given our hypothesis that a decrease in α1-specific [ For the test-retest dataset, α1-and α5-specific [
11 C]Ro15-4513 reliability was calculated using an intra-class correlation coefficient (ICC) based on a two way mixed effect model (Egerton et al., 2010; Shrout and Fleiss, 1979) where ICC values approaching +1 indicate that variance is largely due to between rather than withinsubject variation (Egerton et al., 2010) . Reproducibility was calculated as the percentage test-retest difference (%VAR) (Egerton et al., 2010) : ((retest value-test value)/0.5(test value+retest value)) x 100. All statistical analyses were performed using SPSS 20.0 (SPSS, Chicago, Illinois, USA) and all values are expressed as mean (SD). Power calculations were performed using GPower 3.0 (Faul et al., 2007) .
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Results
Tiagabine behavioural effects
The mean tiagabine dose administered to tiagabine challenge participants was 0.18±0.02 mg/kg. Tiagabine was generally well tolerated, although one participant became symptomatically hypotensive for around an hour at the end of an imaging session. Tiagabine administration produced increases in 'alcohol like drug effect'
(mean±SD placebo and tiagabine scores: 1.2±0.9, 3.9±1.6; p=0.002), disorientation (mean±SD placebo and tiagabine scores: 1.2±0.6, 2.3±0.9; p=0.009), and sedation (mean±SD placebo and tiagabine scores: 1.6±1.4, 2.6±1.6; p=0.09), but had no effect on agitation (mean±SD placebo and tiagabine scores: 1.2±0.6, 1.2±0.6; p=1.0). These effects are similar to those from our previous studies where the main behavioural effects of 15mg tiagabine were described as 'feeling of intoxication', 'dizziness', and 'drug effect is like alcohol' ( 
α1-subtype tiagabine challenge results
Tiagabine administration was associated with reductions in synaptic α1-subtype Table 1 and Figure 4 ).
There were no significant changes in α5-subtype [ 
Correlations with memory performance and behavioural response
Given the suggested role of the hippocampal GABA-BZR in learning and memory in both healthy controls (Collinson et al., 2002; Crestani et al., 2002) Table 2 ). α5-subtype reliability was excellent in the amygdala, anterior cingulate gyrus, nucleus accumbens, amygdala and parahippocampal gyrus (ICC>0.8) and fair in the hippocampus (ICC<0.6). Test-retest variability ranged between 17-38% for the α1-subtype and 0-22% for the α5-subtype.
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Discussion
The main finding of our study is that synaptic α1-subtype [ Reductions in α1-subtype binding after tiagabine administration ranged in magnitude from 61% in the amygdala to 29% in the parahippocampal gyrus and were greater than test-retest variability for every a priori region studied which suggests that they did not arise as a result of chance observations. Moreover, none of these reductions were accompanied by a significant change in regional plasma clearance K 1 , which indicates that they are not a consequence of altered blood flow or ligand delivery. No significant relationships between cognitive measures and changes in [ increase in brain GABA levels (Onoe et al., 1996) . They are also consistent with our a priori hypothesis that an increase in synaptic GABA levels, following tiagabine blockade of GAT1, would reduce the affinity and thus the binding of the inverse that the "GABA shift", well described in-vitro (Braestrup et al., 1982; Onoe et al., 1996; Tallman et al., 1978) , is measurable in humans in vivo. They also suggest that (Frankle et al., 2012) .
Given that the affinity of GABA-BZR's antagonists are reported not to be altered by increases in GABA levels in vitro (Braestrup et al., 1982) these findings would suggest that [ 11 C]flumazenil is acting as a weak agonist in vivo. This is consistent with other in vivo studies where flumazenil appears to behave as a partial agonist (Higgitt et al., 1986; Miller et al., 1988) amenable to bind to the α5-subtype will increase resulting in an apparent increased affinity of the α5-subtype. The change in apparent affinity due to relative changes in the free tracer in tissue has been alternatively defined as increases in "reaction volume" by Delforge and colleagues (Delforge et al., 1996) .
Our findings indicate that increases in limbic synaptic GABA levels are detectable in the living human brain using [ 
26
of the study (n=4), relatively high variability in the α1-specific signal is likely to be a consequence of extracting a comparatively small α1-specific component from the (Frankle et al., 2012) . However as several of our participants reported feeling markedly drowsy after receiving 15mg tiagabine, and as other studies have suggested that tiagabine has the potential to induce stupor (Azar et al., 2013; Hamandi et al., 2014) , we would suggest that any increases in tiagabine dose should be made cautiously.
Although our results require replication and refinement, they have potentially important implications for the investigation of the human GABA-BZR system both in healthy and neuropsychiatric populations. They are particularly relevant for studying how alterations in synaptic GABA levels impact upon normal cognitive processes subserved by the limbic system such as salience, reward, emotional learning and memory; and to explore how increases in synaptic GABA levels differ in disorders where these processes may be abnormal such as anxiety disorders, affective disorders, schizophrenia, addiction and autism. Finally, our findings are also relevant Paul Stokes et al. 27 for the assessment of new treatments designed to increase limbic synaptic GABA levels in neuropsychiatric disorders.
